Clinical trial · Observational
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
NCT06894576CI-TRIAL-00087641CAN-CATCHrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer-associated Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Recurrent VTE
- timeFrame
- 6 months
- description
- The primary outcome of the study will include objectively confirmed recurrent VTE (distal and/or proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and/or splanchnic vein thrombosis and/or cerebral venous sinus thrombosis
Secondary outcomes (2)
- measure
- Overall mortality
- timeFrame
- 6 months
- description
- Post-enrollment follow-up visits will include documentation of death if occuring at any time during the 6 month follow up period
- measure
- Clinically relevant bleeding
- timeFrame
- 6 months
- description
- Post-enrollment follow-up visits will include assessment and documentation of any major and CRNMB and bleeding risk factors at any time during the 6 month follow up period.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types * Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing. * Estimated life expectancy \> 6 months * Willingness to give an informed consent * Age ≥ 18 years Exclusion Criteria: * Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis) * Superficial vein thrombosis * Refusal of informed consent \> 72 hrs of anticoagulants * Age \< 18 years old
References
Publications (0)
Data not yet available
No reference posted for this study.